Belgium · Delayed Price · Currency is EUR Celyad Oncology Statistics
Total Valuation
Celyad Oncology has a market cap or net worth of EUR 8.95 million. The enterprise value is 8.83 million.
| Market Cap | 8.95M |
| Enterprise Value | 8.83M |
Important Dates
The last earnings date was Wednesday, September 23, 2026.
| Earnings Date | Sep 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Celyad Oncology has 44.76 million shares outstanding. The number of shares has increased by 15.71% in one year.
| Current Share Class | 44.76M |
| Shares Outstanding | 44.76M |
| Shares Change (YoY) | +15.71% |
| Shares Change (QoQ) | -12.42% |
| Owned by Insiders (%) | 0.45% |
| Owned by Institutions (%) | 0.08% |
| Float | 14.16M |
Valuation Ratios
The trailing PE ratio is 2.91.
| PE Ratio | 2.91 |
| Forward PE | n/a |
| PS Ratio | 1,278.91 |
| PB Ratio | 7.13 |
| P/TBV Ratio | 7.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.68 |
| EV / Sales | n/a |
| EV / EBITDA | 10.00 |
| EV / EBIT | 9.49 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.94
| Current Ratio | 0.94 |
| Quick Ratio | 0.91 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 21.16 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 14.51% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 66.74% |
| Weighted Average Cost of Capital (WACC) | 11.13% |
| Revenue Per Employee | 1,400 |
| Profits Per Employee | 659,000 |
| Employee Count | 5 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.37% in the last 52 weeks. The beta is 1.25, so Celyad Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | -23.37% |
| 50-Day Moving Average | 0.25 |
| 200-Day Moving Average | 0.27 |
| Relative Strength Index (RSI) | 35.83 |
| Average Volume (20 Days) | 14,868 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celyad Oncology had revenue of EUR 7,000 and earned 3.30 million in profits. Earnings per share was 0.07.
| Revenue | 7,000 |
| Gross Profit | 235,000 |
| Operating Income | 931,000 |
| Pretax Income | 3.30M |
| Net Income | 3.30M |
| EBITDA | 775,000 |
| EBIT | 931,000 |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 121,000 in cash and no debt, with a net cash position of 121,000 or 0.00 per share.
| Cash & Cash Equivalents | 121,000 |
| Total Debt | n/a |
| Net Cash | 121,000 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 1.26M |
| Book Value Per Share | 0.03 |
| Working Capital | -59,000 |
Cash Flow
| Operating Cash Flow | -5.11M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | -156,000 |
| Net Borrowing | -53,000 |
| Free Cash Flow | -5.11M |
| FCF Per Share | -0.11 |
Margins
Gross margin is 3,357.14%, with operating and profit margins of 13,300.00% and 47,071.43%.
| Gross Margin | 3,357.14% |
| Operating Margin | 13,300.00% |
| Pretax Margin | 47,071.43% |
| Profit Margin | 47,071.43% |
| EBITDA Margin | 11,071.43% |
| EBIT Margin | 13,300.00% |
| FCF Margin | n/a |
Dividends & Yields
Celyad Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.71% |
| Shareholder Yield | -15.71% |
| Earnings Yield | 36.81% |
| FCF Yield | -57.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Celyad Oncology has an Altman Z-Score of -211.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -211.22 |
| Piotroski F-Score | 4 |